|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
TRANSPLANTATION
From the Department of Hematology and Oncology,
University of Regensburg, Germany.
Fludarabine is a nonmyeloablative immunosuppressant increasingly
used as a component of alternative conditioning regimens before
allogeneic bone marrow transplantation. It is expected to reduce
conditioning-related toxicity and proinflammatory activation of the
host tissues. However, in our in vitro study, we provide evidence that
2-fluoroadenine 9- Allogeneic stem cell transplantation (SCT) is a
well-established method for the treatment of hematologic neoplasias and
an increasing variety of other malignant disorders. SCT mainly consists of 2 sequential steps: pretransplantation conditioning, classically consisting of total body irradiation (TBI) and chemotherapy and leading
to minimal residual disease and immunosuppression of the recipient, and
transfer of allogeneic stem cells that should provide the cure.
However, because of disparities in major histocompatibility complex
(MHC) and minor histocompatibility antigen (mHAg), severe inflammatory
reactions, including acute graft-versus-host disease (GVHD), can occur
in different phases after transplantation. Based on studies from our
group1 and from several other
investigators,2,3 it is widely accepted that conditioning
contributes through nonspecific inflammation to these
transplantation-related complications. In addition, direct toxicity of
TBI especially has been demonstrated.4,5 This has led to
the investigation of a variety of alternative conditioning
regimens. In addition, new pretransplantation therapies allow
the extension of treatment protocols and patient selection. One
compound of these novel conditioning concepts is fludarabine, a
nonmyeloablative immunosuppressant that had originally been used for
the treatment of chronic lymphatic leukemia.6 Fludarabine in combination with, for example, bis-chloro-nitroso urea (BCNU) and
melphalan, cyclophosphamide, or other agents can replace TBI or is used
together with dose-reduced TBI regimens.7,8 The clinical
data obtained thus far argue for comparably low side effects and for
hematopoietic and immune cell specificity of fludarabine.9 However, the influence of this compound on nonhematopoietic cells, such
as endothelial and epithelial cells, has not yet been investigated.
Virtually all transplantation-related complications are associated with
endothelial dysfunction and damage.10 We and
others11-14 have shown that the endothelium is a target of
pretransplantation conditioning in vitro and in vivo. Ionizing
radiation induces programmed cell death (apoptosis) in endothelial
cells. At the same time, the endothelium is activated in terms of
adhesion molecule expression, leading to increased
leukocyte-endothelial interactions as a prerequisite for
inflammatory processes.15,16 These effects are
significantly enhanced by bacterial endotoxins (lipopolysaccharide) that might translocate through damaged mucosal barriers from the gastrointestinal tract.17 In addition, lipopolysaccharide
has been shown to increase the antigenicity of endothelial cells toward allogeneic CD8+ cytotoxic T lymphocytes.18
These observations prompted us to examine the effects of fludarabine on
viability, activation, and allogenicity of human microvascular
endothelial cells.
Cell culture and reagents
Apoptosis assays
An alternative method for the detection of apoptosis involved microscopic analysis of DNA fluorescence-labeled cells. Endothelial cells (1 × 105/plate) were seeded in 35-mm Petri dishes (Nunc, Wiesbaden, Germany). These cells were treated as described above and subsequently were fixed with methanol-acetone 1:1 for 2 minutes, washed once in PBS, and stained with 4,6-diamidino-2-phenylindole (DAPI; 0.5 µg/mL; Sigma), and dissolved in 20% glycerin-PBS. Samples were mounted and subjected to microscopic analysis. Nuclear condensation as revealed by DAPI staining in the absence of trypan blue uptake is considered characteristic of apoptosis as opposed to necrosis.21 Quantitative analysis included counting the number of apoptotic cells relative to all identifiable cells from at least 10 microscopic fields, with an average of 70 cells per field. For the sake of the clarity of this paper, DAPI stain results are only displayed for the experiments with endothelial cells and HaCaT and with A 549 cells. Cell surface analyses Cell surface expression of intercellular adhesion molecule 1 (ICAM-1; Becton Dickinson/Pharmingen) and MHC class I (w6/32, hybridoma supernatant; American Tissue Culture Collection [ATCC], Manassas, VA) molecules on HMECs was assessed by the indirect immunofluorescence technique and subsequent flow cytometry using the FACScan flow cytometer and the CellQuest analysis program (Becton Dickinson/Pharmingen). Endothelial cells were treated as given and, after incubation, were harvested with trypsin-EDTA (Gibco), washed once in cold PBS-10% FCS, and incubated for 1 hour on ice with 5 µg/mL antiadhesion molecule monoclonal antibodies. Cells were washed again and were incubated with a goat anti-mouse IgG-fluorescein isothiocyanate (FITC)-conjugated antibody F(ab)2 fragment (DAKO, Hamburg, Germany) for 45 minutes on ice. Cells were then washed in PBS-10% FCS and were subjected to analysis. Viability of the cells was determined by concurrent PI (0.2 µg/mL; Sigma) staining. Omitting the first antibody served as a negative control to detect unspecific fluorescence. Using this approach instead of isotype control antibodies was justified by previous observations that endothelial cells lack Fc receptors.22 Therefore, a nonspecific binding of antibodies through their Fc portion could be excluded.Allostimulation of peripheral blood cells with HMECs Peripheral blood mononuclear cells (PBMCs) were derived from heparinized (Novo Nordisk, Mainz, Germany) blood of healthy human volunteers or from buffy coats supplied by the Bavarian Red Cross according to a standard protocol using Ficoll-Hypaque (Pharmacia, Freiburg, Germany) density-gradient centrifugation. Cells were then stimulated at a ratio of 1:1 or 2:1 with irradiated (20 Gy) HMECs for 7 days in the presence of interleukin-2 (IL-2; 50 U/mL) and 10% human AB serum (Sigma). Alternatively, PBMCs were selected for CD8+ T cells and natural killer (NK) cells using cell isolation kits according to the manufacturer's instructions (Magnetic Cell Sorting [MACS]; Miltenyi Biotech, Bergisch-Gladbach, Germany) based on the deletion of non-CD8+ and non-NK cells, respectively. Stimulation of the selected cells was identical to that of whole PBMC cultures, except for NK cells, which were stimulated for only 3 days.Cytotoxicity assay T-cell- or NK-cell-mediated cytotoxicity was assessed according to a well-established protocol,23 using a 4-hour chromium Cr 51 radioisotope assay. HMECs that had been left untreated or were incubated with F-Ara (10 µg/mL) overnight were used as target cells, to be labeled 0.4 mCi (1.48 mBq) Na2 51CrO4 for 2 hours. After 3 washing steps, target cells were adjusted to 104 cells/mL and were coincubated with PBMCs, CD8+ cells, or NK effector cells at descending effector-to-target ratios for another 4 hours. Supernatants were transferred to dry scintillation plates and were counted in a -counter (all from Canberra Packard, Dreieich, Germany). Autologous
(effector) B-lymphoblastoid cell lines (B-LCL) and K562 as NK-sensitive
cells were taken as additional control targets. Percentage specific
lysis was calculated as: [(experimental release  spontaneous
release)/(maximal release spontaneous release)] × 100.
Spontaneous release in all experiments was always lower than
20%.
Enzyme-linked immunosorbent assays Enzyme-linked immunosorbent assay (ELISA) for the detection of IL-4 (Tc2 response) and interferon (IFN-,
Tc1 response), IL-1, and IL-10 in the supernatants of
allogeneic effector T cells (see below) were performed exactly
according to the manufacturer's instructions (R&D Systems,
Minneapolis, MN).
Statistical analysis The significance of differences between experimental values was assessed by means of the Student t test.
F-Ara induces apoptosis in HMECs To assess the influence of F-Ara on the viability of cultured human endothelial cells, HMECs were incubated with descending pharmacologically relevant concentrations (10 µg/mL-0.1 µg/mL) of F-Ara as the metabolized form of fludarabine. The median intracellular level of the active (cytotoxic) fludarabine triphosphate in target cells is 20 µM, representing a concentration 5.8 µg/mL (Medac Schering, Hamburg, Germany; manufacturer's instructions). After 48 hours of incubation, HMECs were subjected to apoptosis assays using the detection of cellular granularity of PI-negative cells (SSC image in flow cytometry) and microscopic analyses of DAPI-stained cells, respectively. Independent of the assay system, Figure 1A-B clearly demonstrates that F-Ara caused apoptosis in HMECs in concentrations of 10 and 5 µg/mL, whereas 1 µg/mL was no longer effective. The critical threshold of the cytotoxicity of F-Ara was between 2 and 3 µg/mL. Apoptosis by F-Ara was already detectable after 24 hours, although to a lesser extent (data not shown).
Defibrotide protects HMECs from the F-Ara-induced apoptosis HMECs had either been left untreated or were treated with F-Ara in the presence or absence of varying concentrations of defibrotide (100 µg/mL-0.1 µg/mL) and were assessed for programmed cell death after 48 hours using flow cytometric analyses of the SSC image as described for Figure 1A. Figure 2A (mid-contour plot) shows that defibrotide alone, as a second control, did not influence endothelial cell viability. The apoptotic effect of F-Ara is reproduced in Figure 2A (right contour plot), whereas Figure 2B shows a dose-dependent protection of F-Ara-induced cell death by defibrotide. To exclude unspecific artifical extracellular interaction of F-Ara and defibrotide in vitro, HMECs were pretreated with defibrotide for 1 hour and subsequently, after 3 washing steps, were incubated with F-Ara for another 48 hours and vice versa. Figure 2C (right contour plot) revealed that pretreatment of HMECs for 1 hour was sufficient to protect cells from F-Ara-induced apoptosis. Similarly, pretreatment of HMEC with F-Ara for 1 hour (Figure 2C, left contour plot) and subsequent incubation with defibrotide did not lead to endothelial programmed cell death.
Effect of F-Ara on different epithelial cell lines: protective effect of defibrotide Skin, the gastrointestinal tract (GIT), and most likely the lung are among the primary targets of GVHD. Therefore, it was reasonable to test the influence of F-Ara on cell lines derived from these organs. Cells from keratinocyte (HaCaT), GIT (SW 480), alveolar (A549) cells lines, bronchial epithelial (BEAS-2B) cell lines, and primary bronchial epithelial cells were incubated with F-Ara (10 µg/mL) as for Figures 1 and 2 and assayed in flow cytometric apoptosis analyses 48 hours after treatment. Figure 3A summarizes that gut and bronchial epithelial cells appeared to be resistant to the apoptotic stimuli of F-Ara, whereas keratinocytes (HaCaT) and alveolar epithelial cells (A549) showed signs of apoptosis, as determined by flow cytometry of the SSC image (34.0% ± 1.0% apoptotic cells for HaCaT and 42.9% ± 26.7% for A549, respectively). Again, the protective potential of defibrotide (100 µg/mL) was assessed. HaCaT (4.3% ± 3.0%) and A549 (5.4% ± 2.9%) cells were completely protected from programmed cell death after cotreatment with F-Ara and defibrotide (Figure 3A, inset bar graphs). To confirm these results, DAPI-stain apoptosis assays were performed for HaCAT (Figure 3B, left columns) and A549 cells (Figure 3B, right columns). As shown for endothelial cells, defibrotide alone did not influence the number of apoptotic cells in either cell line (data not shown).
Defibrotide does not interfere with the antileukemic and anti-PBMC effects of F-Ara Next to its desirable protective capacity for endothelial and epithelial cells against F-Ara-induced apoptosis, it was important to investigate whether defibrotide would also interfere with the antileukemic properties of F-Ara. To address this question, primary peripheral blood-derived acute myeloid leukemic (AML) cells with a blast amount of 70% were thawed, kept in culture for 24 hours, and subsequently treated with F-Ara in the presence or absence of defibrotide for another 48 hours. Figure 4A demonstrates that already almost 50% of the cells died spontaneously of necrotic cell death. However, F-Ara induced cell death in up to 80% of the cells. In contrast to its effect on endothelial and epithelial cells, defibrotide was unable to protect AML cells from F-Ara-mediated toxicity. It is of note that Figure 4A describes percentage vitality of the cells, not percentage apoptotic cells, because F-Ara directly caused necrosis rather than apoptosis in AML cells. This could be observed as early as 24 hours of incubation. Still, Figure 4A clearly shows that defibrotide does not interfere with the desirable toxicity of F-Ara against leukemic cells. We next asked whether defibrotide might modulate the effect of F-Ara against normal hematopoietic cells and performed apoptosis assays (SSC image) with PBMCs from healthy human blood donors. As could be learned from a representative experiment depicted in Figure 4B, F-Ara induced apoptosis in 40.1% of the cells compared with 5.1% apoptotic cells in the untreated control. Again, defibrotide did not interfere with the apoptotic activity of F-Ara against PBMCs (43.1% apoptotic cells), suggesting that the immunosuppressive properties of F-Ara are not harmed by cotreatment with defibrotide.
F-Ara up-regulates ICAM-1 on HMECs with antagonistic effects of defibrotide Based on previous observations that pretransplantation conditioning not only damages but also leads to proinflammatory activation of endothelial cells in terms of adhesion molecule induction,15 we next investigated the expression of ICAM-1 under the influence of F-Ara. As depicted in Figure 5A-B, flow cytometric analyses demonstrated that F-Ara, after 24 hours of incubation, significantly enhances the expression on HMECs in a dose-dependent manner, similar to that observed for apoptosis induction. Concentrations as small as 1 µg/mL F-Ara were effective in inducing ICAM-1. We next asked whether defibrotide would also be functional as an antagonist of F-Ara in this experimental setting. HMECs were treated with F-Ara, as given and incubated in the presence or absence of descending concentrations of defibrotide. Figure 5C summarizes 3 independent experiments showing that defibrotide in fact antagonized F-Ara-induced ICAM-1 expression in concentrations of 100 µg/mL and 10 µg/mL. Defibrotide alone did not activate endothelial cells, and ICAM-1 expression remained unchanged with every concentration tested (data not shown).
Because a proinflammatory activation of target cells is often associated with increased expression of MHC class I and class II, we conducted further flow cytometric analyses for these antigens after incubation with F-Ara in various concentrations for 24 hours. Despite its well-described immunosuppressive properties, F-Ara surprisingly induced MHC class I molecules on HMECs dose dependently (1.5-fold induction of mean fluorescence intensity at 10 µg/mL, 1.3-fold induction at 5 µg/mL), whereas MHC class II remained unchanged (data not shown). F-Ara increases the antigenicity of endothelial cells toward allogeneic peripheral blood cells: protection by defibrotide The induction of MHC class I molecules on HMECs by F-Ara prompted us to examine whether F-Ara would also enhance the capacity of HMECs to stimulate allocytotoxic responses. PBMCs as effectors were either derived from heparinized blood of healthy human volunteers of from buffy coat preparations, stimulated with irradiated (20 Gy) HMECs in the presence of 50 U/mL IL-2 for 7 days, and subsequently subjected to a standard 51Cr release assay (for details, see "Materials and methods"). At day1, fresh HMECs as targets were
either left unstimulated or were incubated with F-Ara (10 µg/mL) in
the presence or absence of an anti-MHC class I neutralizing antibody
(w6/32). Autologous effector Epstein-Barr virus-transformed B-LCL and
K562 cells as classical NK cell targets served as controls. Figure
6A demonstrates that F-Ara indeed
increased the antigenicity of HMECs toward allogeneic PBMCs at all
effector: target (E/T) ratios tested. The lack of specific lysis of
K562 and autologous effector B-LCLs verified the involvement of
MHC-restricted cytotoxic T lymphocytes (CTLs). In addition, lysis of
either untreated or F-Ara-treated HMECs could almost fully be blocked
after coincubation of these cells with the anti-MHC class I antibody
w6/32 (Figure 6A, * ). To further confirm that CD8+ CTLs
were responsible for the antiendothelial cytotoxic activity, PBMCs were
selected for CD8+ and CD4+ T cells (non-CD8-
and non-CD4-depleted PBMCs, respectively) using magnetic bead
separation with MACS bead kits. Purity of the preparations was 93% or
more in all cases with a complete absence of the other cell populations
(not shown). Separated T cells were stimulated with HMECs and IL-2
exactly as described for unselected PBMCs (see above). As shown in
Figure 6B, lysis of F-Ara-treated HMECs by CD8+ CTLs was,
again, significantly higher than that of control HMECs. Furthermore,
pretreatment of target HMECs with F-Ara and defibrotide (F-Ara+D)
down-regulated specific lysis even below control levels, suggesting
that defibrotide also protects endothelial cells against the lysis of
allogeneic effector lymphocytes. HMEC-stimulated CD4+ T
cells did not show any signs of cytotoxic activity in this experimental
setting (data not shown). Flow cytometric analyses of F-Ara versus
F-Ara+D-treated HMECs resulted in a significant down-regulation of MHC
class I molecules by defibrotide, suggesting that MHC class I
expression is the critical element in regulating the cytotoxic response
induced by F-Ara (data not shown).
Antiendothelial CTLs display a Tc1-like phenotype To gain information about the nature of antiendothelial CTLs, PBMCs and CD8+ T cells were stimulated as given above, and supernatants were collected for the assessment of IFN- and IL-4
using ELISA analyses. As depicted in Table
1, stimulation with HMECs and IL-2
obviously led to the outgrowth of Tc1-like T cells, as
could be told from the unique expression of IFN-, whereas no IL-4
was produced.
F-Ara down-regulates lysis of HMECs by allogeneic NK cells Another interesting question was how F-Ara-induced modulations of MHC class I expression affects the cytolytic response of NK cells against endothelial cells. PBMCs from healthy persons were negatively selected for NK cells (non-NK-cell depleted) and were stimulated for 4 days with irradiated HMECs in the presence of IL-2, as it was described for the experiment in Figure 6B. At day 4, HMECs as target cells were left untreated or were incubated with F-Ara (10 µg/mL) for 24 hours and subjected to a standard 51Cr release assay with the stimulated NK cells as effectors. Figure 7 demonstrates that F-Ara significantly down-regulated the allogenicity of HMEC toward NK cells. As a positive control for NK cell activity, lysis of MHC class I-negative K562 cells could be observed (Figure 7, *). Pretreatment of F-Ara-stimulated
HMECs with the anti-MHC class I antibody w6/32 completely abrogated the
effect of F-Ara and led to almost 100% specific lysis of HMECs (Figure
7), suggesting that MHC class I on the surface of HMECs is, again, the
critical switch for the regulation of the cytotoxic response of NK
cells. The role of killer cell inhibitory receptors, found to be
negatively regulated by high expression levels of MHC class I
molecules,24 might be responsible for the decreased
cytolytic response of NK cells.
Clinical results with fludarabine-containing reduced-intensity
conditioning regimens obtained so far show a clear down-regulation of
conditioning-related toxicity without affecting immune
reconstitution.25 The incidence of acute GVHD in patients
receiving reduced-intensity conditioning is comparable or even less
than that in patients receiving the classical conditioning
regimen.26 However, equally severe or even increased late
effects such as osteonecrosis (E. H., personal communication, June
2001), pulmonal complications,27 and more cases of
chronic GVHD arise.28 Despite its well-documented immunosuppressive properties, fludarabine, in our study, activated and
damaged endothelial and epithelial cells. This observation might, at
least in part, explain the undesired clinical side effects described
above because osteonecrosis is an expression of endothelial dysfunction, and fludarabine appears to be toxic for alveolar epithelial cells. It is interesting to note that the harmful effects of
fludarabine on lung cells seem to be compartment specific In many pretransplantation protocols fludarabine is used in combination with ionizing radiation, so it was important to test whether these 2 compounds would cooperate in affecting endothelial cells. Interestingly, we could not find any enhancement of radiation-induced cell death by fludarabine or vice versa (data not shown). This suggests differential mechanisms of how the apoptotic death signal is transferred to endothelial cells. In addition, it remains to be investigated how far other conditioning agents such as cyclophosphamide, BCNU, or melphalan affect the viability and allogenicity of endothelial cells alone or in combination with fludarabine. This is subject to ongoing studies in our laboratory. The precise mechanism regarding how fludarabine induces apoptosis in endothelial and epithelial cells remains to be elucidated. It is likely that fludarabine, as a purin analogue, integrates into the DNA and thus causes mutations that lead to gene deletion like those reported previously.29 It has also been suggested that fludarabine can cooperate with cytochrome c and apoptosis protein-activating factor-1 in triggering the apoptotic caspase pathway.30 Fludarabine increases the allogenicity of endothelial cell
targets for CD8+ T cells. In contrast, fludarabine
significantly down-modulates endothelial lysis by allogeneic NK cells.
MHC class I expression seems to be critical for the regulation of any
of these immune responses because a blockade of class 1 fully abrogated
CTL lysis and tremendously up-regulated lysis by NK cells. These
opposing effects of fludarabine, taken together with the clinical
observation that fludarabine shows less acute and equal or even more
chronic toxicity than the classical conditioning regimen, raises the
speculation that NK cells and CTLs might be active in different phases
of GVHD pathophysiology With regard to the nature of antiendothelial CTLs, it is an interesting
question whether these CTLs are endothelial-specific or simply
allo-specific. The existence of endothelial-specific effector
lymphocytes has been described.31 In contrast to the CTLs
we characterized as displaying a Tc1-like phenotype, many of the CTL
clones reported show little, if any, IFN- Defibrotide is a well-tolerated drug that is successfully used for the treatment of veno-occlusive disease as one major hepatic complication after SCT.33 In addition, an increasing number of preclinical and clinical reports show its efficacy in treating ischemia-reperfusion injury, atherosclerosis, and recurrent thrombotic thrombocytopenic purpura.34-36 Defibrotide is known to act directly on endothelial cells without the requirement for further metabolism37 and could, therefore, be used in our in vitro studies. Defibrotide fully protected endothelial and epithelial cells from fludarabine-mediated apoptosis. Additional experimentation is needed to assess the precise mechanism of protection by which defibrotide antagonizes fludarabine, but one can imagine a role for defibrotide in the inhibition of DNA integration of fludarabine or the aforementioned caspase activation. Besides its antiapoptotic effects, defibrotide was able to down-regulate antiendothelial CTL responses by regulating MHC class I expression. In contrast, defibrotide did not affect the desirable antileukemic effect of fludarabine, as shown by the lack of protection of AML cells. This promising result still has to be confirmed by testing other hematologic malignancies to exclude that defibrotide does not interfere with the antitumor response. However, another important observation was that defibrotide could not block fludarabine-mediated apoptosis of PBMC. This suggests that the immunosuppressant effect of fludarabine mandatory for conditioning would not be influenced by cotreatment with defibrotide. Defibrotide did not protect against radiation-induced endothelial cell damage, suggesting that its effect was specific for fludarabine-mediated cellular changes (data not shown). Based on these results and with respect to its few, if any, side effects,38 we conclude that defibrotide might be a good candidate used in combination with fludarabine during conditioning before SCT, especially in patients at risk for veno-occlusive disease. Studies analyzing endothelial protection against further conditioning agents should help clarify whether defibrotide can be used as a broad protective agent.
We thank Drs Christian Schulz and Petra Smyczek for providing primary bronchial epithelial cells and the cell lines A549 and BEAS-2B, Dr Klaus Schlottmann for providing SW 480 cells, and Karin Fischer for providing primary AML cells.
Submitted November 5, 2001; accepted February 27, 2002.
Supported by grants Ei68/1-1 and 2-1-2 from the Deutsche Forschungsgemeinschaft.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Günther Eissner, Department of Hematology and Oncology, University of Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany; e-mail: guenther.eissner{at}klinik.uni-regensburg.de.
1.
Holler E, Kolb HJ, Möller A, et al.
Increased serum levels of tumor necrosis factor
2.
Antin JH, Ferrara JLM.
Cytokine dysregulation and acute graft-versus-host disease.
Blood.
1992;80:2964-2968 3. Ferrara JL, Levy R, Chao NJ. Pathophysiological mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347-356[CrossRef][Medline] [Order article via Infotrieve]. 4. Xun CQ, Brown BA, Jennings CD, Henslee-Downey PJ, Thompson JS. Acute graft-versus-host-like diseases induced by transplantation of human activated natural killer cells into SCID mice. Transplantation. 1993;56:409-417[Medline] [Order article via Infotrieve].
5.
Weiner RS, Bortin MM, Gale RP, et al.
Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors.
Ann Intern Med.
1986;104:168-175 6. Weiss MA. Novel treatment strategies in chronic lymphocytic leukemia. Curr Oncol Rep. 2001;3:217-222[Medline] [Order article via Infotrieve]. 7. Wasch R, Reisser S, Hahn J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243-250[CrossRef][Medline] [Order article via Infotrieve]. 8. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350[CrossRef][Medline] [Order article via Infotrieve].
9.
Slavin S, Nagler A, Naparstek E, et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Blood.
1998;91:756-763
10.
Holler E, Kolb HJ, Hiller E, et al.
Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.
Blood.
1989;73:2018-2024
11.
Eissner G, Kohlhuber F, Grell M, et al.
Critical involvement of transmembrane TNF-
12.
Lindner H, Holler E, Ertl B, et al.
Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines.
Blood.
1997;89:1931-1938
13.
Haimovitz-Friedman A, Balaban N, Mcloughlin M, et al.
Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis.
Cancer Res.
1994;54:2591-2597
14.
Fuks Z, Persaud RS, Alfieri A, et al.
Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo.
Cancer Res.
1994;54:2582-2590 15. Eissner G, Lindner H, Behrends U, et al. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: protective role of IL-10. Transplantation. 1996;62:819-827[CrossRef][Medline] [Order article via Infotrieve]. 16. Lindner H, Holler E, Gerbitz A, Johnson JP, Bornkamm GW, Eissner G. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: 2. IL-10 protects against transendothelial migration. Transplantation. 1997;64:1370-1973[Medline] [Order article via Infotrieve].
17.
Beelen DW, Haralambie E, Brandt H, et al.
Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation.
Blood.
1992;80:2668-2676 18. Eissner G, Multhoff G, Holler E. Influence of bacterial endotoxin on the allogenicity of human endothelial cells. Bone Marrow Transplant. 1998;21:1286-1287[CrossRef][Medline] [Order article via Infotrieve]. 19. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683-690[CrossRef][Medline] [Order article via Infotrieve].
20.
Cotter TG, Lennon SV, Glynn JM, Green DR.
Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis.
Cancer Res.
1992;52:997-1005 21. Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 1993;54:283-288[Abstract]. 22. Westphal JR, Tax WJ, Willems HW, Koene RA, Ruiter DJ, De-Waal RM. Accessory function of endothelial cells in anti-CD3-induced T-cell proliferation: synergism with monocytes. Scand J Immunol. 1992;35:449-457[CrossRef][Medline] [Order article via Infotrieve]. 23. MacDonald HR, Engers HD, Cerrottini JC, Brunner KT. Generation of cytotoxic T lymphocytes in vitro. J Exp Med. 1974;140:718-722[Abstract]. 24. Long E. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904[CrossRef][Medline] [Order article via Infotrieve]. 25. Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-370[CrossRef][Medline] [Order article via Infotrieve].
26.
Michallet M, Bilger K, Garban F, et al.
Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.
J Clin Oncol.
2001;19:3340-3349 27. Hildebrandt G, Bertz H, Mestan A, et al. Analysis of pulmonary function after allogeneic bone marrow transplantation (BMT) or blood stem cell transplantation (PBSCT) using conditioning regimens with total body irradiation (TBI) and conventional intensity compared to regimens without TBI with reduced intensity [abstract]. Bone Marrow Transplant. 2001;27(suppl 1):S216. 28. Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. 2000;26:119-125[CrossRef][Medline] [Order article via Infotrieve]. 29. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutat Res. 1989;210:291-301[CrossRef][Medline] [Order article via Infotrieve].
30.
Genini D, Budihardjo I, Plunkett W, et al.
Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway.
J Biol Chem.
2000;275:29-34
31.
Biederman BC, Pober JS.
Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL.
J Immunol.
1999;162:7022-7030 32. Briscoe DM, Alexander AI, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr Opin Immunol. 1998;10:525-531[CrossRef][Medline] [Order article via Infotrieve]. 33. Pegram AA, Kennedy LD. Prevention and treatment of veno-occlusive disease. Ann Pharmacother. 2001;35:935-942[Abstract]. 34. Rossini G, Pompilio G, Biglioli P, et al. Protectant activity of defibrotide in cardioplegia followed by ischemia/reperfusion injury in the isolated rat heart. J Card Surg. 1999;14:334-341[Medline] [Order article via Infotrieve]. 35. Rossini G, Berti F, Trento F, et al. Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit. Thromb Res. 2000;97:29-38[CrossRef][Medline] [Order article via Infotrieve].
36.
Pogliani EM, Perseghin P, Parma M, Pioltelli P, Corneo G.
Defibrotide in recurrent thrombotic thrombocytopenic purpura.
Clin Appl Thromb Hemost.
2000;6:69-70 37. San T, Moini H, Emerk K, Bilsel S. Protective effect of defibrotide on perfusion induced endothelial damage. Thromb Res. 2000;99:335-341[CrossRef][Medline] [Order article via Infotrieve]. 38. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122-1129[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. S. Mitsiades, C. Rouleau, C. Echart, K. Menon, B. Teicher, M. Distaso, A. Palumbo, M. Boccadoro, K. C. Anderson, M. Iacobelli, et al. Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias Clin. Cancer Res., February 15, 2009; 15(4): 1210 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Eissner, J. Wiesner, N. Hahn, M. Iacobelli, M. Haubitz, R. Andreesen, and E. Holler In Vitro Monitoring of Defibrotide Prophylaxis for Endothelial Complications Following Allogeneic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2969 - 2969. [Abstract] [PDF]
|
|
|
|
 |
|
 W. J. Hogan, M. Maris, B. Storer, B. M. Sandmaier, D. G. Maloney, H. G. Schoch, A. E. Woolfrey, H. M. Shulman, R. Storb, and G. B. McDonald Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients Blood, January 1, 2004; 103(1): 78 - 84. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-D-arabinofuranoside (F-Ara) as the
active metabolized form of fludarabine damages human microvascular endothelial cells (HMECs) and dermal and alveolar epithelial cell lines
after 48 hours of culture when it is used in pharmacologically relevant
concentrations (range, 10 µg/mL-1 µg/mL). In addition, flow
cytometric analyses revealed a significant up-regulation of
intercellular adhesion molecule 1 and major histocompatibility complex
(MHC) class I molecules by F-Ara, suggesting a proinflammatory activation of HMECs. Cytotoxicity assays demonstrated that target HMECs
pretreated with F-Ara (10 µg/mL) showed increased lysis by allogeneic
MHC class I-restricted cytotoxic T lymphocytes from healthy human
donors. We conclude that, beside its immunosuppressive activities,
F-Ara can be harmful for target tissues of transplantation-related complications and can even stimulate allogeneic immune responses. We
identified the pharmaceutical compound defibrotide as protective against F-Ara- induced apoptosis and alloactivation, importantly, without affecting the antileukemic effect of F-Ara. This observation argues for a potential clinical usage of defibrotide in
pretransplantation conditioning.
(Blood. 2002;100:334-340)
/CD16+CD56+.
*
precede major complications of bone marrow transplantation.
Blood.
1990;75:1011-1016